Hypertroponinemia, Structural Cardiac Disease, and Stroke Mortality

Roever, Leonardo; Resende, Elmiro Santos; Roerver-Borges, Anaisa Silva

doi:10.1161/strokeaha.117.017061

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 This low mortality might be attributed to our inclusion criterion of AIS and exclusion criterion of death within a month. Previous studies have suggested many biomarkers in predicting mortality of stroke, such as cardiac troponin T, 34 amino-terminal pro-B-type natriuretic peptide, 35 total cholesterol, 36 γ-glutamyl transferase, 37 estimated glomerular filtration rate, 38 and neurofilament light 39 et al Several inflammatory parameters are also meaningful in the prediction of stroke mortality. Patients with increased serum levels of procalcitonin (PCT) and C-reactive protein (CRP) have a higher mortality at 3 month or even 1 year after the index stroke.…”

Section: Discussionmentioning

confidence: 99%

Systemic Immune-Inflammation Index and Long-Term Mortality in Patients with Stroke-Associated Pneumonia

Xie¹,

Yuan²,

Zhu³

et al. 2023

JIR

View full text Add to dashboard Cite

Background: Systemic immune inflammation has been investigated as a prognostic marker of different diseases. This study is designed to assess the association of systemic immune-inflammation index (SII) with long-term mortality of stroke-associated pneumonia (SAP) patients. Methods: Patients aged ≥18 years with SAP were selected from the Nanjing Stroke Registry Program in China. We retrospectively evaluated systemic immune-inflammation response with SII and pneumonia severity with the pneumonia severity index and the confusion, uremia, elevated respiratory rate, hypotension, and aged 65 years or older score. To explore the correlation between SII and mortality in SAP patients, multivariable Cox regressions and competing risk regressions were conducted. Mediation analysis was also performed to assess the role of pneumonia severity. Results: Among 611 patients in the SAP population, death occurred in 164 patients (26.8%) during the median follow-up of 3.0 (1.2-4.6) years. In multivariate analysis, higher SII scores could predict increased mortality in patients with SAP (adjusted hazard ratio 2.061; 95% confidence interval, 1.256-3.383; P = 0.004), and the association was mediated by pneumonia severity. Moreover, adding SII to traditional models improved their predictive ability for mortality. Conclusion: Our study displayed that SII was characterized in SAP patients with different prognoses. Elevated SII scores increased the risk of mortality. Further research is required for the clinical practice of the index among SAP patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic Immune-Inflammation Index and Long-Term Mortality in Patients with Stroke-Associated Pneumonia

Xie¹,

Yuan²,

Zhu³

et al. 2023

JIR

View full text Add to dashboard Cite

show abstract

“…These three subunits of troponin complex along with tropomyosin is located on the actin filament and is essential for the calcium-mediated regulation of skeletal and cardiac muscle contraction. 6,7 Among the three troponins, TnT and TnI are being used as the biochemical markers for the diagnosis of myocardial injury. The amino acid sequence of cardiac troponin-T and troponin-I is different from that present in skeletal muscles.…”

Section: Introductionmentioning

confidence: 99%

“…This is a base for cardiac troponin specificity in the diagnosis of myocardial injury. 7 Normally, about 94-97% of TnT and TnI are bound to myofibril and only 6% of cTnT and 3% of the cTnI are free in the cytoplasm, but during myocardial damage, the cytosolic troponin reaches the bloodstream quickly resulting in a rapid peak of serum troponin observed during the first few hours. Next, the release of structurally bound troponin results in a second peak lasting for several days.…”

Section: Introductionmentioning

confidence: 99%

Cardiac Troponin-I Status of Type-2 Diabetic Patients on Anti-Diabetic Drugs Treatment at Jimma Medical Center, Jimma, Southwest Ethiopia

Wega¹,

Wabalo²,

Edae³

et al. 2021

RRCC

View full text Add to dashboard Cite

Introduction: Metabolic abnormalities of type-2 diabetes mellitus cause vascular dysfunction which is manifested with common cardiovascular complications such as atherosclerosis, myocardial infarction (MI), stroke, and coronary heart diseases. In spite of all these complications, there is no literature revealing the cardiac status of type-2 diabetic patients, in general and on different anti-diabetic drugs in particular, using cardiac troponin-I as a biomarker in study area and Ethiopia too. Objective of the Study: This study was, therefore, aimed to assess cardiac troponin-I in type-2 diabetic patients on anti-diabetic drugs treatment at Jimma Medical Center, Jimma, Southwest Ethiopia. Methods: To achieve the objectives of the study, a facility based cross-sectional study was conducted among type-2 diabetic patients on follow-up at Jimma Medical Center from August 1 to September 30, 2020. Systematic sampling technique was used to select 82 study participants. A 5mL of venous blood was drawn from each participant after overnight fasting using an aseptic technique and centrifuged at 3000 rpm for 10 minutes. Multiple logistic regression analysis and one way ANOVA were used for statistical data analysis. P-value <0.05 was considered as statistically significant. Results: The prevalence of elevated cardiac troponin-I was 25.6% in the study population. The mean value of serum cardiac troponin-I was lower in patients who were on metformin monotherapy as compared to patients on insulin monotherapy (11.654 ± 1.6795 versus 20.573 ± 1.8402, P<0.01). It was also lower when compared with those patients on metformin + glibenclamide combination therapy (11.654 ± 1.6795 versus 21.094 ± 2.4062, P<0.01). Conclusion and Recommendations: About 1/4 th of the study participants had elevated serum cardiac troponin-I level. Metformin monotherapy significantly reduced serum cTnI levels as compared to insulin monotherapy and metformin + glibenclamide combination therapy. Regular screening for cardiac injury using cardiac troponin-I is recommended for type-2 diabetic patients.

show abstract